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Objective: We investigated whether levels of current physical activity (PA) contribute 
to the established relationship between cardiorespiratory fitness (CRF) and cognition 
in schizophrenia and whether brain-derived neurotrophic factor (BDNF) or its precursor 
proBDNF mediates this relationship.
Method: Sixty-one outpatients with schizophrenia spectrum disorders participated. 
Neurocognition was assessed with the Wechsler Adult Intelligence Scale (WAIS) and 
nine subtests from the MATRICS battery comprising a neurocognitive composite score 
(NCS). CRF was assessed with peak oxygen uptake (VO2peak) measured directly during a 
maximum exercise test. Current PA levels were objectively assessed by an accelerometer 
worn for four consecutive days. BDNF and proBDNF were measured in fasting blood. 
Four serial parallel mediation analyses and two additional parallel mediation analyses were 
conducted, while controlling for age and sex at all levels.
Results: No direct effects were found between PA measures and WAIS or NCS. No 
significant mediating effects of CRF or BDNF/proBDNF were detected.
Conclusion: The results do not support the hypothesis that PA contributes to the 
naturally occurring relationship between CRF and cognition in schizophrenia or the 
hypothesis that BDNF or proBDNF mediates this relationship. The results arguably 
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INTRODUCTION
Individuals with schizophrenia display profoundly low 
levels of cardiorespiratory fitness (CRF) (1–4) and impaired 
cognition is a clinical feature in schizophrenia (5, 6). Thus, the 
relationship between CRF and cognition is of special interest 
with regard to this patient group. In a previous study, we 
found that CRF explained 8.2% and 9.0% of the variance in 
general intellectual ability (IQ) and state-sensitive cognitive 
functions (processing speed, attention, working memory, 
learning and executive functions), respectively (6, 7). The 
association between CRF and cognition appeared significant 
beyond the impact of negative psychotic symptom load and 
other potential confounders. Moreover, the association was 
explained by a modality-specific relationship between CRF 
and a verbal cognitive factor (5, 7).
Moderate to vigorous physical activity (MVPA), as in 
exercise, is a central CRF-enhancing lifestyle factor (8). A meta-
analysis of 10 exercise intervention studies with individuals with 
schizophrenia reported significant effects of increased CRF on 
overall cognitive performance, as well as for specific domains such 
as working memory, attention/vigilance, and social cognition (9). 
Hence, higher levels of MVPA may improve cognition through 
increased CRF. Conversely, better cognitive abilities may provide 
better opportunities for a healthy lifestyle, including higher levels 
of MVPA and thus improved CRF, and these factors may interact 
in a mutually reinforcing manner (10). Presumably, such effects 
would be reflected in current naturally occurring associations 
between physical activity (PA) and cognition, in which CRF would 
appear as a mediator. One study has shown positive associations 
between moderate PA and measures of processing speed and verbal 
working memory among 30 older individuals with schizophrenia 
(aged >55) (11). Another study showed associations between light 
PA and tasks measuring attention/concentration and speed of 
processing in a sample of 199 individuals with schizophrenia (12). 
However, none of these studies included measures of CRF or other 
potential mediators to these relationships. In a previous study, 
we found that only a more general and less vigorous indicator of 
current PA, number of steps per day, was significantly associated 
with CRF in schizophrenia (13). This indicates that variation in 
CRF among individuals with schizophrenia, being less fit than 
the population at large, should be studied with measures sensitive 
to less intensive PA—such as walking (steps per day). There may 
also be routes of influence between PA and cognition which do 
not involve CRF. For example, the bioenergetic effects hypothesis 
centers on the mediating role of brain-derived neurotrophic factor 
(BDNF) (14).
BDNF plays a modulating role in dopamine, serotonin, and 
GABA systems (15) and is associated with neuronal development 
and plasticity through synaptic long-term potentiation (16, 17) 
and, thus, with learning and memory. BDNF may traverse the 
blood-brain barrier, indicating that systemic levels may reflect 
brain levels. Individuals with schizophrenia are characterized by 
low circulating levels of BDNF, and there is a positive association 
between levels of BDNF and reasoning/problem solving in 
schizophrenia (18). BDNF in its precursory form, proBDNF, 
may have effects opposite from its mature version (19), which 
bespeaks the complexity of its functions. One study has shown 
that cognitive remediation leads to an increase in BDNF in 
individuals with schizophrenia (20); however, this was not 
replicated in a slightly larger sample (21). Moreover, Kimhy and 
colleagues found that aerobic exercise improved levels of BDNF 
in a sample of individuals with schizophrenia, as compared 
to controls (22). Aerobic exercise and other forms of PA may 
influence the blood-brain barrier permeability and the release of 
growth factors, including BDNF, in central and peripheral tissue. 
PA may also contest metabolism-related, proinflammatory 
processes which obstruct the production and functioning of 
growth factors, including BDNF (23). Consequently, BDNF may 
act as a mediator between PA and cognition. Such an effect may 
be related directly to acute bouts of PA, such as exercise, but also 
to long-term low level PA sustained over time (23).
CRF as measured by maximal oxygen uptake (VO2peak) 
explains some of the variance in cognition in schizophrenia (6). 
It is not clear what causes this relationship or what mediates it. In 
the present study, we investigated the potential impact of PA on 
cognition through the potentially mediating levels of CRF and 
BDNF/proBDNF. In previous studies, we have shown that CRF is 
associated with cognition in schizophrenia and also that a general 
measure of PA in steps per day—but not the more intensive 
measure of MVPA—is associated with CRF (6, 13). However, 
whether the effect of steps extends from CRF to cognition, and 
whether steps or MVPA influences cognition directly or through 
the second mediating level of BDNF, has not been assessed. The 
pathways are visualized in Figure 1.
We hypothesize that current levels of PA (steps per day and 
MVPA) will be positively associated with cognition in this 
sample of individuals with schizophrenia, with CRF and/or 
BDNF mediating the relationship between PA and cognition. 
To explore the potential role of BDNFs precursor in this model, 
we will include proBDNF as an alternative mediator. We will 
analyze these relationships through four mediation analyses; 
with steps and MVPA as alternating independent variables and 
two different composite measures of cognition as alternating 
dependent variables; with CRF, BDNF, and proBDNF as serial 
and parallel mediators respectively; while controlling for age and 
sex at all levels in the models.
support the assumption that the association between CRF and cognition in schizophrenia 
is established developmentally early.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02205684.
Keywords: psychosis, schizophrenia, cognition, physical, activity, exercise, CRF, BDNF
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MATERIALS AND METHODS
Design
The study was conducted on baseline data from the randomized, 
controlled, observer-blinded clinical trial “Effects of Physical 
Activity in Psychosis” (EPHAPS) [ClinicalTrials.gov, registration 
number NCT02205684 (24)]. The study was approved by the 
Regional Committee for Medical and Health Research Ethics 
of Southern and Eastern Norway (file number 2014/372/REK 
SØR-ØST).
Participants
Sixty-one participants aged 20–64 years were recruited from 
August 2014 through February 2017 from catchment area-
based and publicly funded outpatient psychiatric clinics 
in Vestfold County, Norway. A subgroup of patients was 
referred from primary health care to the outpatient clinics 
for participation in the project specifically. Eligible for 
the study were patients who fulfilled the Diagnostic and 
Statistical Manual of Mental Disorders (5th ed.; DSM-V; 25) 
criteria for schizophrenia spectrum disorder (schizophrenia, 
schizoaffective disorder, and schizophreniform disorder). 
Demographic and clinical characteristics are presented in 
Table 1. Diagnosis was established using the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental 
Disorders axis I [SCID I (26)]. Interviews were conducted by 
a clinical psychologist or a specialist in psychiatry. Members 
of the assessment staff attended a course based on the SCID 
training program at the University of California Los Angeles 
(27) and all participated in diagnostic consensus meetings. 
Additional inclusion criteria were age between 18 and 67 
and understanding and speaking a Scandinavian language. 
Exclusion criteria were pregnancy, chest pain during CRF 
test, unstable angina pectoris, recent myocardial infarction, 
uncontrollable cardiac arrhythmia, severe hypertension 
(>180/110 mmHg), comorbid diagnosis of mild mental 
retardation, or other medical conditions incompatible with 
participation. Initial information about the study was given 
to eligible patients by clinical staff in the outpatient clinic or 
in primary health services. Contingent on understanding the 
nature of the research and willingness to participate, written 
consent was obtained by a project coworker.
Sixty participants received antipsychotic medical treatment. 
Defined daily doses (DDD) were calculated in accordance with 
guidelines from the World Health Organization Collaborating 
Center for Drug Statistics Methodology (http://www.whocc.no/
atcdd). The DDD is the assumed average maintenance dose per 
day for a drug used for its main indication on adults, providing 
a fixed unit of measurement independent of dosage form and 
thus a rough estimate of pharmaceutical drugs consumption. 
Furthermore, 13 participants received antidepressant medication, 
nine of which contained selective serotonin reuptake inhibitors.
Procedure
The current study was based on neurocognitive and clinical 
assessments, a CRF test, a blood test from which BDNF and 
TABLE 1 | Demographic and clinical characteristics of participants (n = 61).
Attribute Mean (SD)
Male n = 34 (56%)
Age (years) 36.4 (13.3)
Education (years) 12.2 (2.4)
Duration of illness (years) 14.7 (11.7)
GAF-S1* 43.6 (7.7)
GAF-F2* 44.4 (7.9)
PANSS3 total 64.2 (17.3)
WAIS-IV GAI4 88.0 (16.2)
MCCB NCS5 35.0 (8.3)





Antipsychotics DDD10 ** 1.7 (0.9)
1Global Assessment of Functioning-Symptom scale; 2 Global Assessment of 
Functioning-Function scale; 3Positive and Negative Syndrome Scale;
4Wechsler Adult Intelligence Scale version IV General Ability Index.
5MATRICS Consensus Cognitive Battery Neurocognitive
Composite Score.
6Moderate and vigorous physical activity, minutes per day;
7Number of steps per day; 8Brain-derived neurotrophic factor;
9Pro-brain-derived neurotrophic factor. 10Defined Daily Doses.
*Data on GAF-scores were missing for one individual.
**Sixty individuals received antipsychotic medication.
FIGURE 1 | The effect of MVPA and Steps on WAIS GAI and MCCB NCS, directly and through VO2peak and/or BDNF and proBDNF (n = 61): Visualization of pathways. 
1Moderate and vigorous physical activity, minutes per day. 2Number of steps per day. 3VO2peak: ml/kg/min. 4Brain-derived neurotrophic factor. 5Pro-brain-derived 
neurotrophic factor. 6Wechsler Adult Intelligence Scale version IV General. Ability Index. 7MATRICS Consensus Cognitive Battery Neurocognitive. Composite Score.
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proBDNF were extracted, and accelerometer data. All assessments 
were conducted within a two-week period. Neurocognition was 
assessed with the six subtests of the Wechsler Adult Intelligence 
Scale version 4 (2008, NCS Pearson Inc. San Antonio, TX, USA), 
which comprise the General Ability Index (WAIS-IV GAI) and 
may be regarded as a core IQ measure not contaminated by 
state-dependent reductions in processing speed and memory. 
Furthermore, nine of the 10 subtests in the MATRICS consensus 
cognitive battery were applied as measures of the state-sensitive 
cognitive functions, yielding a neurocognitive composite score 
(MCCB NCS). The MCCB NCS assesses cognitive functioning 
in six domains: speed of processing, attention/vigilance, working 
memory, verbal learning, visual learning, and problem solving 
(28). The Norwegian version of MCCB has retained the original 
psychometric properties (29) with the possible exception of the 
test intended to measure social cognition (the Mayer-Salovey-
Caruso Emotional Intelligence Test), which was not included in 
the current study.
Peak oxygen uptake (VO2peak) was measured during a maximum 
exercise test on a treadmill using a modified Balke protocol (30), 
where speed was held constant at 5 km/h and the inclination 
angle was increased by one degree every minute until exhaustion. 
Gas exchange was sampled continuously into a mixing chamber 
every 30 s by having the participants breathe into a Hans Rudolph 
two-way breathing valve (2,700 series, Hans Rudolph Inc., Kansas 
City, MO, USA) connected to a Jaeger Oxycon Pro gas analyzer 
(Erich Jaeger GmbH, Hoechberg, Germany), which measures the 
oxygen and carbon dioxide content. Before conducting the CRF 
test, somatic health was thoroughly assessed through general 
medical examination, including medical history, medication 
record, and physical examination with blood pressure assessment 
and electrocardiography. For various reasons, some individuals 
may fail to reach a true VO2max, and for the sake of conservative 
reporting, we therefore use the term VO2peak.
PA was assessed using the GT3X+ accelerometer from 
Actigraph (ActiGraph, LLC, Pensacola, FL, USA). Participants 
were instructed to wear the accelerometer over the left hip while 
awake for four consecutive days. In order to ensure an even 
distribution between the two-week phases, the participants were 
instructed to use the accelerometer for two weekdays and the two 
weekend days. The accelerometer is a seismic instrument which 
continuously measures acceleration, and raw data from this 
instrument are called “counts,” which are the sum of accelerations 
in a given time period (4). Analyses were restricted to participants 
who wore the accelerometer for a minimum of 10 h per day for 
two days or more. MVPA is defined as the number of minutes 
spent in all activity ≥ 2020 counts per minute and calculated from 
the number of minutes spent at this activity level per day. “Steps” 
is the registered number of steps per day. Participants who wore 
the monitor for two days or more were included in the analysis 
(n = 61). 9 participants wore the accelerometer for 2 days, 13 wore 
it for 3 days, 37 wore it for 4 days, and 2 wore it for 5 days.
Fasting blood samples were obtained from all participants 
during morning hours within the two-week assessment period. 
Samples were processed to platelet poor plasma and frozen 
at  −80°C within 2 h. Enzyme immunoassay development kits 
from R&D Systems (Stillwater, MN) were used to measure 
proBDNF (DY3175) and BDNF (DY248). Intraassay and 
interassay variation was <10%.
Statistical Analysis
Analyses of skewness and kurtosis indicated that data were 
normally distributed for the two measures of cognition (WAIS 
GAI and MCCB NCS) and CRF. One outlier was identified for 
both MVPA and steps and recoded into the second highest value 
in the data set. Two outliers were identified for proBDNF and 
recoded into the third highest value in the data set. The variables 
of MVPA, steps, and BDNF were log-transformed.
Statistical analyses were made using The Statistical Package 
for the Social Sciences (IBM SPSS Version 22.0, IBM Corp, 
Armonk, NY, USA), with the addition of the PROCESS program 
for mediation/moderation analyses (31). Four serial parallel 
mediation analyses and two additional parallel mediation 
analyses were conducted with PROCESS, using ordinary least 
squares path analysis. Significance levels were set at 5% for all 
analyses of direct effects between independent and dependent 
variables. 95% bootstrap confidence intervals with iteration 
set to 10,000 were calculated for all indirect effects involving 
mediators [unstandardized effects, as recommended by Hayes 
(31)]. The four main analyses included MVPA and steps as 
alternating independent variables and WAIS GAI and MCCB 
NCS as alternating dependent variables, and with VO2peak, BDNF, 
and proBDNF as serial and parallel mediators respectively, while 
controlling for age and sex at all levels in the models. Pathways 
are visualized in Figure 1.
Accelerometer data were obtained for 61 participants, whereas 
BDNF and proBDNF data were available for 78 participants. In 
order to maximize utilization of data, two additional analyses 
were done with sole focus on the mediating effects of BDNF and 
proBDNF as parallel mediators in this slightly larger sample. 
VO2peak was entered as independent variable and WAIS GAI and 
MCCB NCS as alternating dependent variables, while controlling 
for age and sex at all levels in the models.
RESULTS
Four serial parallel mediation analyses using ordinary least squares 
path analysis were conducted (n = 61), and no significant direct 
effects were found between MVPA or steps on one side and WAIS 
GAI or MCCB NCS on the other (MVPA–WAIS GAI: c’ = −4.47, 
p = 0.37; MVPA–MCCB NCS: c’ = −3.27, p = 0.22; steps–WAIS 
GAI: c’ = −10.04, p = 0.24; steps–MCCB NCS: c’ = −2.26, p = 0.63). 
Bootstrap confidence intervals based on 10,000 bootstrap samples 
for all indirect effects in all analyses all included zero, prohibiting 
rejection of respective null hypotheses, thus leaving any mediation 
effects from VO2peak and/or BDNF and/or proBDNF nonsignificant. 
Two additional parallel mediation analyses (n = 78) showed direct 
effects between VO2peak and both WAIS GAI (c’ = 0.58, p = 0.01) and 
MCCB NCS (c’ = 0.31, p = 0.01), as expected from previous studies 
(6, 7). However, results from the main analyses were retained; no 
significant mediating effects from BDNF or proBDNF were found 
in this slightly increased sample. All indirect effects, with respective 
bootstrap confidence intervals, are presented in Table 2.
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DISCUSSION
In the current study, neither MVPA nor steps appeared to exert 
significant effects on cognition either directly or indirectly through 
any of the mediators. Moreover, neither BDNF nor proBDNF 
appeared to mediate the relationship between CRF and cognition.
Five hypotheses have been proposed on specific mediator 
mechanisms between PA and cognition (14). The cardiovascular 
fitness hypothesis holds that improved oxygen transport and 
metabolism lead to improved neurotransmitter function (32), 
and the cerebrovascular reserve hypothesis points to the ability 
of cerebral blood vessels to respond to increased metabolic 
demand and chemical, mechanical, or neural stimuli (33). The 
motor fitness hypothesis focuses on differential ripple effects 
from increased movement- and coordination-specific perceptual 
and cognitive demand (14). In a similar vein, the selective 
improvements hypothesis suggests that executive functions have 
the greatest potential to respond to aerobic exercise, as these are 
disproportionately affected by ageing (34). Finally, and partly in 
response to phenomena unexplained by these theories such as 
rapid improvements in cognition shortly after physical exercise 
(35), the bioenergetic effects hypothesis centers on the mediating 
role of BDNF. It focuses on this growth factor’s ability to enhance 
cellular energy metabolism and reduce oxidative stress; animal 
studies on blocking BDNF-receptors in the hippocampus indicate 
that physical fitness alone does not improve cognition (36).
The current results do not lend support to the bioenergetic 
effects hypothesis. None of the two measures of BDNF appeared 
to have any significant mediating effect between PA/CRF and 
cognition. Furthermore, in a previous study (5), we did not 
find support for the effects proposed by the motor fitness or the 
selective improvements hypotheses to be present in this sample 
of individuals with schizophrenia. There was no evidence of a 
proximal link between CRF and cognitive functions believed 
to be more involved during exercise, or a selective effect on 
executive functions. Contrarily, we found that CRF was 
selectively associated with a verbal cognitive factor. However, 
it must be noted that the proposed effect of the motor fitness 
hypothesis is not limited to CRF-enhancing activities but 
includes also less metabolically demanding activities such 
as coordination tasks. Any such non-CRF-dependent effects 
would not have been detected in this previous study. Moreover, 
we have previously established that number of daily steps is 
associated with CRF (13), and that CRF is associated with 
cognition (6, 7). Still, the current results show that the effect 
does not carry over from steps, via CRF, to cognition. This 
indicates independent, partial effects between steps and CRF 
and between CRF and cognition respectively, and/or a signal 
not strong enough to bear through the mediating level of CRF. 
Thus, the results appear equivocal as to the presence of effects 
proposed by the cerebrovascular reserves and cardiovascular 
fitness hypotheses. Also, the results do not support a 
complementary sixth hypothesis of a converse or reciprocal 
effect between cognition and PA- that individuals with higher 
cognitive functioning become more physically active.
There may be alternative reasons why we do not find support 
for the hypothesized effects. Importantly, the first five hypotheses 
described above primarily address mechanisms behind reported 
effects of various exercise interventions, which may not be present 
in the naturally occurring, long-term developing relationships 
between the same variables. Such relationships may be limited 
to a subsample of participants who regularly engage in exercise, 
and otherwise overshadowed by other factors, such as common 
genetic factors behind CRF, cognition, and/or schizophrenia. 
For example, BDNF is associated with CRF, cognition, and 
schizophrenia (18, 23, 37), and a mediating role between CRF 
and cognition may be obscured by disorder-specific effects in 
schizophrenia.
The study has some limitations. Although the objective 
assessment of PA provides validity (38), the limited number of 
days the participants wore the accelerometer (two to five) may 
have compromised the representativeness of the measure. Diurnal 
and daily variations in BDNF, for a variety of reasons, may have 
occluded its potentially mediating effect between PA/CRF and 
cognition. This includes the possible impacts of menstrual phase 
for the female participants and selective serotonin reuptake 
inhibitors for the nine participants receiving medication 
containing this active substance. In this study, we have sought to 
further explain an established relationship between the relatively 
stable attributes of CRF and cognition, by considering the roles 
of two presumably less stable factors of PA and BDNF. The 
potential variability of these may have obstructed the detection 
of genuine effects. Moreover, in the absence of a control group, 
TABLE 2 | Mediation effects (n = 61).
Path Mediation 
effect
95% bootstrap CI 
(LL, UL)
MVPA1-VO2peak2-WAIS GAI3  0.64 –2.05, 4,16
MVPA-BDNF4-WAIS GAI –0.21 –2.06, 1.45
MVPA-proBDNF5-WAIS GAI –0.05 –1.91, 2.00
MVPA-VO2peak-BDNF-WAIS GAI –0.03 –0.59, 0.32
MVPA-VO2peak-proBDNF-WAIS GAI  0.05 –0.31, 0.66
MVPA-VO2peak-MCCB NCS6  0.37 –1.21, 2.39
MVPA-BDNF-MCCB NCS  0.10 –0.83, 1.25
MVPA-proBDNF-MCCB NCS –0.02 –0.85, 0.89
MVPA-VO2peak-BDNF-MCCB NCS  0.02 –0.26, 0.26
MVPA-VO2peak-proBDNF-MCCB NCS  0.02 –0.15, 0.25
Steps7-VO2peak-WAIS GAI  3.88 –1.69, 12.71
Steps -BDNF-WAIS GAI  0.01 –2.28, 2.12
Steps-proBDNF-WAIS GAI  0.16 –2.74, 5.05
Steps-VO2peak-BDNF-WAIS GAI –0.21 –1.86, 0.79
Steps-VO2peak-proBDNF-WAIS GAI  0.23 –0.73, 1,92
Steps-VO2peak-MCCB NCS  1.97 –1.85, 6.37
Steps-BDNF-MCCB NCS  0.00 –1.42, 1.25
Steps-proBDNF-MCCB NCS  0.07 –1.38, 1.91
Steps-VO2peak-BDNF-MCCB NCS  0.05 –0.74, 0.84
Steps-VO2peak-proBDNF-MCCB NCS  0.10 –0.38, 0.73
VO2peak-BDNF-WAIS GAI* –0.03 –0.15, 0.04
VO2peak-proBDNF-WAIS GAI*  0.00 –0.05, 0.08
VO2peak-BDNF-MCCB NCS* –0.01 –0.07, 0.03
VO2peak-proBDNF-MCCB NCS*  0.00 –0.03, 0.03
1Moderate and vigorous physical activity, minutes per day; 2VO2peak: ml/kg/min; 
3Wechsler Adult Intelligence Scale version IV General Ability Index.
4Brain-derived neurotrophic factor; 5Pro-brain-derived neurotrophic factor; 6MATRICS 
Consensus Cognitive Battery Neurocognitive Composite Score.
7Number of steps per day; *Additional analyses with BDNF and proBDNF as sole 
mediators (n = 78).
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we do not know whether the results are specific for individuals 
with schizophrenia or also apply to the general population.
In previous studies, we have found that the naturally occurring 
association between CRF and cognition in schizophrenia is tied 
to a verbal cognitive factor, on which the Verbal Comprehension 
Index of WAIS IV loads highly (7). We have found no indications 
of a stronger link between CRF and cognitive functions thought 
to be more state-sensitive or modifiable through life-style factors 
(6). Furthermore, we found that the relationship between CRF 
and cognition could not be explained by current lifestyle related 
factors such as metabolism-based illnesses or smoking. In the 
current study, we detected no significant influence from present 
levels of PA on the association between CRF and cognition. Also, 
no mediating effects of BDNF or its precursor proBDNF were 
found in the relationships between PA/CRF and cognition, in 
this sample. Lastly, there was no indication that the association 
between CRF and cognition can be explained by better cognitively 
functioning individuals being more active.
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